DISSOLVE 1&2 SEL 212 = tolerogenic nanoparticles containing rapamycin (SEL-110) + pegadricase (SEL-037) Meets primary endpoint in 2 RCTs High dose response 56% & 46% 97% reduction in sUA Infusion reaction 4%, stomatitis 8% Anaphylaxis 4 cases @RheumNow #EULAR23 LB0002 https://t.co/21HieM7NfC